Accuray Incorporated

NasdaqGS ARAY

Accuray Incorporated Price to Book Ratio (P/B) on January 14, 2025: 4.94

Accuray Incorporated Price to Book Ratio (P/B) is 4.94 on January 14, 2025, a -7.57% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Accuray Incorporated 52-week high Price to Book Ratio (P/B) is 5.66 on January 22, 2024, which is 14.42% above the current Price to Book Ratio (P/B).
  • Accuray Incorporated 52-week low Price to Book Ratio (P/B) is 3.05 on August 12, 2024, which is -38.29% below the current Price to Book Ratio (P/B).
  • Accuray Incorporated average Price to Book Ratio (P/B) for the last 52 weeks is 4.33.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
NasdaqGS: ARAY

Accuray Incorporated

CEO Ms. Suzanne Winter M.B.A.
IPO Date Feb. 8, 2007
Location United States
Headquarters 1240 Deming Way
Employees 987
Sector Health Care
Industries
Description

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Similar companies

FNA

Paragon 28, Inc.

USD 10.28

-4.28%

ANIK

Anika Therapeutics, Inc.

USD 15.58

-2.14%

OFIX

Orthofix Medical Inc.

USD 17.51

0.81%

NPCE

NeuroPace, Inc.

USD 11.84

-2.23%

SGHT

Sight Sciences, Inc.

USD 3.15

-2.78%

AXGN

AxoGen, Inc.

USD 18.24

-0.06%

SRDX

Surmodics, Inc.

USD 35.55

-0.81%

TELA

TELA Bio, Inc.

USD 2.74

-1.44%

AORT

Artivion, Inc.

USD 29.68

1.16%

BVS

Bioventus Inc.

USD 8.87

-3.17%

SIBN

SI-BONE, Inc.

USD 15.70

-3.27%

AVNS

Avanos Medical, Inc.

USD 15.83

0.19%

APYX

Apyx Medical Corporation

USD 1.43

-4.03%

KIDS

OrthoPediatrics Corp.

USD 23.55

-5.80%

CLPT

ClearPoint Neuro, Inc.

USD 14.70

-4.54%

StockViz Staff

January 15, 2025

Any question? Send us an email